

This article was downloaded by: [University of Saskatchewan Library]

On: 19 November 2014, At: 20:40

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/gpss20>

Synthesis of Novel Piperazine Phosphoramidate Analogues of 2-Arylquinolones

Zhibo Qu^a, Xiaolan Chen^a, Lingbo Qu^{a,b}, Jinwei Yuan^b, Huina Li^a & Yufen Zhao^{a,c}

^a Key Laboratory of Organic Chemistry and Chemical Biology, Henan Province, Department of Chemistry, Zhengzhou University, Zhengzhou, P. R. China

^b School of Chemistry & Chemical Engineering, Henan University of Technology, Henan Province, Zhengzhou, P. R. China

^c Key Laboratory for Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, School of Life Sciences and Engineering, Tsinghua University, Beijing, P. R. China

Published online: 02 Jul 2010.

To cite this article: Zhibo Qu, Xiaolan Chen, Lingbo Qu, Jinwei Yuan, Huina Li & Yufen Zhao (2010) Synthesis of Novel Piperazine Phosphoramidate Analogues of 2-Arylquinolones, *Phosphorus, Sulfur, and Silicon and the Related Elements*, 185:7, 1516-1520, DOI: [10.1080/10426500903120750](https://doi.org/10.1080/10426500903120750)

To link to this article: <http://dx.doi.org/10.1080/10426500903120750>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

SYNTHESIS OF NOVEL PIPERAZINE PHOSPHORAMIDATE ANALOGUES OF 2-ARYLQUINOLONES

Zhibo Qu,¹ Xiaolan Chen,¹ Lingbo Qu,^{1,2} Jinwei Yuan,²
Huina Li,¹ and Yufen Zhao^{1,3}

¹Key Laboratory of Organic Chemistry and Chemical Biology, Henan Province, Department of Chemistry, Zhengzhou University, Zhengzhou, P. R. China

²School of Chemistry & Chemical Engineering, Henan University of Technology, Henan Province, Zhengzhou, P. R. China

³Key Laboratory for Bioorganic Phosphorus Chemistry and Chemical Biology, Ministry of Education, Department of Chemistry, School of Life Sciences and Engineering, Tsinghua University, Beijing, P. R. China

A series of novel piperazine phosphoramidate derivatives of 2-arylquinolones were synthesized to improve their physicochemical and biological properties through a facile phosphorylating reaction. Their structures were elucidated by NMR, ESI MS, and HRMS.

Keywords 2-Arylquinolones; piperazine phosphoramidate; synthesis

INTRODUCTION


2-Arylquinolones are a class of molecules used as aza analogues of flavones. Consequently, synthesis and structural modification of the derivatives of 2-arylquinolone have attracted much interest. Pharmacological research has demonstrated that 2-arylquinolones exhibit many important physiological activities, to act as potent cytotoxic, antimetabolic, antibacterial, and antiplatelet agents, and have cardiovascular protecting properties.^{1–4}

The introduction of a phosphate group essentially changes the physical and chemical properties of the parent molecule, resulting in changes of the polarization and intermolecular bonding characteristics.^{5–7} Moreover, phosphates and phosphoramidates have been widely used as prodrug moieties to enhance the water solubility and have proven to be exceedingly important agents for anticancer and antiviral therapy.^{8–13} Piperazines also exhibit many physiological activities. They can act as platelet-activating factor antagonists, potential antipsychotic agents, dopamine transporter inhibitors, and antitumor agents.^{14–17} Our interest was to synthesize a series of phosphoryl piperazine linked 2-arylquinolone derivatives to improve their physicochemical and biological properties. A novel type of

Received 2 March 2009; accepted 11 June 2009.

The authors would like to thank the Chinese National Science Foundation (No. 20472076) and Henan Academic Foundation of Science and Technology (No. 0512001400) for their financial support.

Address correspondence to Xiaolan Chen and Yufen Zhao, Department of Chemistry, Zhengzhou University, 75 Daxue Road, Henan Province, Zhengzhou 450052, P.R. China. E-mail: chenxl@zzu.edu.cn



5	a	b	c	d	e	f
R ₁	H	H	H	H	Cl	Cl
R ₂	H	H	H	CH ₃	H	H
R ₃	H	CH ₃	Cl	CH ₃	CH ₃	Cl

Scheme 1 Synthesis of piperazine phosphoramidate analogues of 2-arylquinolones **5a–f**.

phosphoramidate derivatives of 2-arylquinolones was synthesized by a facile phosphorylating reaction (Scheme 1).

RESULTS AND DISCUSSION

To synthesize the piperazine phosphoramidate analogues of 2-arylquinolones (**5**) (Scheme 1), bis(β -chloroethyl)amine hydrochloride, the arylamine, and potassium carbonate were refluxed in *n*-butyl alcohol for 28 h. The solid was filtered off. The crystalline *N*-aryl piperazine (**1**) was obtained after the filtrate was cooled down to room temperature. Phenyl dichlorophosphates (**2**) were coupled with different *N*-aryl piperazine to achieve phenyl aminophosphorochloridates (**3**), which were used without further purification. 2-Arylquinolones (**4**) were reacted with the phenyl aminophosphorochloridates (**3**) in the presence of triethylamine in THF to form the piperazine phosphoramidate analogues of 2-arylquinolones (**5**). The 2-arylquinolones (**4**) were expected to experience tautomerization to their 4-hydroquinol isomers (**4'**) under basic conditions. The structures of all newly synthesized 2-arylquinolone derivatives were confirmed by ESI MS, HRMS, and NMR.

EXPERIMENTAL

All experiments involving water-sensitive compounds were conducted under scrupulously dry conditions. ^1H , ^{13}C , and ^{31}P NMR spectra were recorded on a Bruker Avance DPX spectrometer operating at 400.13, 100.61, and 161.98 MHz, respectively, with ^{13}C and ^{31}P spectra being recorded proton-decoupled. All NMR spectra were recorded in CDCl_3 at room temperature ($20 \pm 3^\circ\text{C}$). ^1H and ^{13}C chemical shifts are quoted in ppm downfield from TMS. ^{31}P chemical shifts are quoted in ppm relative to an external 85% H_3PO_4 standard. Coupling constants J are given in Hz, and the signal splitting patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), or combinations thereof. TLC was performed on silica gel plates and preparative chromatograph on columns of silica gel (200–300 mesh). HRMS were recorded on a Q-ToF Micro spectrometer.

N-Arylpiperazine (1)

Bis(β -chloroethyl)amine hydrochloride (6.4 g, 0.0358 mol), arylamine (3.2 mL, 0.0358 mol), and K_2CO_3 (5.0 g) were refluxed in *n*-butanol (60 mL) for 28 h. The excess of K_2CO_3 was filtered off, then the solvent was cooled to room temperature and the *N*-arylpiperazine (**1**) was crystallized.

Phosphochloridate (3)

The phosphodichloridate (**2**) (1.05 g, 5.0 mmol) and the *N*-arylpiperazine (**1**) (1.0 g, 5.0 mmol) were suspended in anhydrous dichloromethane (30 mL). Anhydrous NET_3 (1.4 mL, 10.0 mmol) was added dropwise at -50°C during 10 min, and then the reaction mixture was left to rise to room temperature. After 8 h, the solvent was evaporated under reduced pressure, and the residue was washed with anhydrous ether and filtered. The filtrate was evaporated to dryness under reduced pressure. The crude phosphochloridate (**3**) was obtained and used without further purification.¹⁸

Piperazine Phosphoramidate Analogues of 2-Arylquinolones (5)

Anhydrous NET_3 (0.4 mL, 3 mmol) was added dropwise to a solution of the appropriate phosphorochloridate (**3**) (0.9 g, 2.7 mmol) and 2-arylquinolone (**4**) (0.5 g, 1.8 mmol) in anhydrous THF at room temperature. The reaction mixture was refluxed for 6–10 h and then cooled to room temperature. The precipitated NHET_3Cl was filtered off, and the filtrate was evaporated under reduced pressure to give the residues as yellow powders. The crude product (**5**) was purified by column chromatography on silica gel (cyclohexane:AcOEt, 1:2).

Compound 5a. Yellow powder, mp $147\text{--}148^\circ\text{C}$, yield 41%. HRMS 582.2157 [$\text{M} + \text{H}$]⁺ (calculated for $\text{C}_{33}\text{H}_{32}\text{N}_3\text{O}_5\text{P}$ 581.2080). ^1H NMR: δ 3.04 (t, 4 H, $^3J_{\text{P-H}} = 4.8$, H-11/13), 3.48–3.54 (m, 4 H, H-12/14), 3.89 (s, 3 H, 7-OCH₃), 3.95 (s, 3 H, 5-OCH₃), 6.53 (d, 1 H, $^4J_{\text{H-H}} = 2.3$, H-6), 6.84–6.89 (m, 3 H, H-2''/4''/6''), 7.12 (d, 1 H, $^4J_{\text{H-H}} = 2.3$, H-8), 7.15–7.17 (m, 1 H, H-4'''), 7.18–7.26 (m, 2 H, H-3'''/5'''), 7.29–7.36 (m, 4 H, H-3''/5''/2'''/6'''), 7.42–7.50 (m, 3 H, H-3'/4'/5'), 7.89 (d, 1 H, $^4J_{\text{P-H}} = 1.3$, H-3), 8.09–8.10 (m, 1 H, H-2'), 8.09–8.10 (m, 1 H, H-6'). ^{13}C NMR: δ : 44.7 (C-12/14, d, $^3J_{\text{P-C}} = 1.7$), 49.7 (C-11/13, d, $^2J_{\text{P-C}} = 5.6$), 55.7 (7-OCH₃), 55.9 (5-OCH₃), 99.4 (C-6), 100.9 (C-8), 107.1 (C-3, d, $^3J_{\text{P-C}} = 3.0$), 108.4 (C-10, d, $^3J_{\text{P-C}} = 6.6$), 116.7 (C-2'''/6'''), 120.2 (C-2'''/6''', d,

$^3J_{P-C} = 5.1$, 120.5 (C-4''), 125.1 (C-4'''), 127.5 (C-2'/6'), 128.8 (C-3'/5'), 129.2 (C-3''/5''), 129.6 (C-4'), 129.8 (C-3'''/5'''), 138.8 (C-1'), 150.8 (C-1'''), d, $^2J_{P-C} = 6.7$, 151.2 (C-1''), 153.6 (C-9), 155.5 (C-4, d, $^2J_{P-C} = 6.9$), 156.7 (C-5), 158.8 (C-2), 161.4 (C-7). ^{31}P NMR: $\delta -2.88$.

Compound 5b. Yellow powder, mp 151–152°C, yield 49%. HRMS 596.2312 [M + H]⁺ (calculated for C₃₄H₃₄N₃O₅P 595.2236). 1H NMR: δ 2.40 (s, 3 H, 4'-CH₃), 3.03 (t, 4 H, $^3J_{P-H} = 4.8$, H-11/13), 3.47–3.52 (m, 4 H, H-12/14), 3.87 (s, 3 H, 7-OCH₃), 3.94 (s, 3 H, 5-OCH₃), 6.51 (d, 1 H, $^4J_{H-H} = 2.2$, H-6), 6.82–6.88 (m, 3 H, H-2''/4''/6''), 7.11 (d, 1 H, $^4J_{H-H} = 2.2$, H-8), 7.16–7.18 (m, 1 H, H-4'''), 7.27–7.36 (m, 6 H, H-2'''/3'''/5'''/6'''/3'/5'), 7.20–7.25 (m, 2 H, H-3'/5'), 7.88 (d, 1 H, $^4J_{P-H} = 1.3$, H-3), 8.00 (d, $^3J_{H-H} = 4.1$, 1 H, H-2'), 8.02 (d, $^3J_{H-H} = 4.1$, 1 H, H-6'). ^{13}C NMR: δ 44.7 (C-12/14), 49.7 (C-11/13, d, $^2J_{P-C} = 5.5$), 55.6 (7-OCH₃), 55.9 (5-OCH₃), 99.3 (C-6), 100.9 (C-8), 106.9 (C-3, d, $^3J_{P-C} = 3.0$), 108.3 (C-10, d, $^3J_{P-C} = 6.7$), 116.7 (C-2''/6''), 120.2 (C-2'''/6'''), d, $^3J_{P-C} = 5.0$), 120.5 (C-4''), 125.1 (C-4'''), 127.3 (C-2'/6'), 129.2 (C-3'/5'), 129.5 (C-3''/5''), 129.8 (C-3'''/5'''), 136.0 (C-4'), 139.7 (C-1'), 150.8 (C-1'''), d, $^2J_{P-C} = 6.9$), 151.2 (C-1''), 153.6 (C-9), 155.4 (C-4, d, $^2J_{P-C} = 6.7$), 156.7 (C-5), 158.8 (C-2), 161.3 (C-7). ^{31}P NMR: $\delta -2.63$.

Compound 5c. Yellow powder, mp 156–157°C, yield 32%. HRMS 616.1772 [M + H]⁺ (calculated for C₃₃H₃₁ClN₃O₅P 615.1690). 1H NMR: δ 3.05 (t, 4 H, $^3J_{P-H} = 4.9$, H-11/13), 3.49–3.54 (m, 4 H, H-12/14), 3.89 (s, 3 H, 7-OCH₃), 3.95 (s, 3 H, 5-OCH₃), 6.54 (d, 1 H, $^4J_{H-H} = 2.2$, H-6), 6.84–6.89 (m, 3 H, H-2''/4''/6''), 7.09 (d, 1 H, $^4J_{H-H} = 2.2$, H-8), 7.15–7.19 (m, 1 H, H-4'''), 7.22–7.36 (m, 6 H, H-3'''/5'''/3'/5'/2''/6''), 7.46 (d, 2 H, $^3J_{H-H} = 2.2$, H-3'/5'), 7.85 (d, 1 H, $^4J_{P-H} = 1.1$, H-3), 8.04 (d, 2 H, $^3J_{H-H} = 6.8$, $^4J_{H-H} = 1.7$, H-2'/6'). ^{13}C NMR: δ 44.7 (C-12/14), 49.7 (C-11/13, d, $^2J_{P-C} = 5.5$), 55.6 (7-OCH₃), 55.9 (5-OCH₃), 99.6 (C-6), 100.9 (C-8), 106.7 (C-3, d, $^3J_{P-C} = 2.8$), 108.5 (C-10, d, $^3J_{P-C} = 6.9$), 116.7 (C-2''/6''), 120.1 (C-2'''/6'''), d, $^3J_{P-C} = 4.9$), 120.6 (C-4''), 125.2 (C-4'''), 128.7 (C-2'/6'), 128.9 (C-3'/5'), 129.2 (C-3''/5''), 129.8 (C-3'''/5'''), 135.8 (C-4'), 137.2 (C-1'), 150.8 (C-1'''), d, $^2J_{P-C} = 7.2$), 151.2 (C-1''), 153.6 (C-9), 155.7 (C-4, d, $^2J_{P-C} = 6.7$), 156.7 (C-5), 157.4 (C-2), 161.5 (C-7). ^{31}P NMR: $\delta -2.59$.

Compound 5d. Yellow powder, mp 153–154°C, yield 43%. HRMS 610.2471 [M + H]⁺ (calculated for C₃₅H₃₆N₃O₅P 609.2393). 1H NMR: δ 2.28 (s, 3 H, 4'-CH₃), 2.42 (s, 3 H, 3''-CH₃), 3.02 (t, 4 H, $^3J_{P-H} = 4.8$, H-11/13), 3.47–3.52 (m, 4 H, H-12/14), 3.88 (s, 3 H, 7-OCH₃), 3.95 (s, 3 H, 5-OCH₃), 6.52 (d, 1 H, $^4J_{H-H} = 2.2$, H-6), 6.64–6.70 (m, 3 H, H-2''/4''/6''), 7.11 (d, 1 H, $^4J_{H-H} = 2.3$, H-8), 7.12–7.17 (m, 1 H, H-5''), 7.16–7.18 (m, 1 H, H-4'''), 7.26–7.36 (m, 6 H, H-2'''/3'''/5'''/6'''/3'/5'), 7.87 (d, 1 H, $^4J_{P-H} = 1.2$, H-3), 8.01 (d, 2 H, $^3J_{H-H} = 8.2$, H-2'/6'). ^{13}C NMR: δ 21.3 (4'-CH₃), 21.7 (3''-CH₃), 44.7 (C-12/14), 49.8 (C-11/13, d, $^2J_{P-C} = 5.5$), 55.6 (7-OCH₃), 55.9 (5-OCH₃), 99.3 (C-6), 100.9 (C-8), 106.9 (C-3), 108.3 (C-10, d, $^3J_{P-C} = 6.7$), 117.6 (C-2''/6''), 120.2 (C-2'''/6'''), d, $^3J_{P-C} = 5.0$), 121.4 (C-4''), 125.1 (C-4'''), 127.3 (C-2'/6'), 129.5 (C-3'/5'), 129.0 (C-5''), 129.8 (C-3'''/5'''), 136.0 (C-3''), 137.7 (C-1'), 138.9 (C-4'), 150.8 (C-1'''), d, $^2J_{P-C} = 6.6$), 151.3 (C-1''), 153.6 (C-9), 155.4 (C-4), 156.7 (C-5), 157.7 (C-2), 161.3 (C-7). ^{31}P NMR: $\delta -2.65$.

Compound 5e. Yellow powder, mp 160–161°C, yield 47%. HRMS 630.1921 [M + H]⁺ (calculated for C₃₄H₃₃ClN₃O₅P 629.1846). 1H NMR: δ 2.41 (s, 3 H, 3''-CH₃), 2.99 (t, 4 H, $^3J_{P-H} = 4.8$, H-11/13), 3.46–3.51 (m, 4 H, H-12/14), 3.88 (s, 3 H, 7-OCH₃), 3.95 (s, 3 H, 5-OCH₃), 6.52 (d, 1 H, $^4J_{H-H} = 2.3$, H-6), 6.73–6.76 (m, 2 H, H-2''/6''), 7.11 (d, 1 H, $^4J_{H-H} = 2.3$, H-8), 7.15–7.19 (m, 2 H, H-3'/5'), 7.26–7.36 (m, 7 H, H-3''/5''/2'''/3'''/4'''/5'''/6'''), 7.86 (d, 1 H, $^4J_{P-H} = 1.3$, H-3), 7.99 (d, 2 H, $^3J_{H-H} = 1.7$, H-2'/6'). ^{13}C NMR: δ 21.4 (4''-CH₃), 44.5 (C-12/14, d, $^3J_{P-C} = 2.1$), 49.7 (C-11/13, d, $^2J_{P-C} = 5.6$), 55.6 (7-OCH₃), 55.9 (5-OCH₃), 99.3 (C-6), 100.9 (C-8), 106.9 (C-3, d, $^3J_{P-C} = 3.1$), 108.3 (C-10, d, $^3J_{P-C} =$

6.4), 117.9 (C-2''/6''), 120.2 (C-2'''/6''', d, $^3J_{P-C} = 5.0$), 125.2 (C-4''), 125.5 (C-4'''), 127.3 (C-2'/6'), 129.1 (C-3'/5'), 129.5 (C-3''/5''), 129.8 (C-3'''/5'''), 136.0 (C-4'), 139.8 (C-1'), 149.8 (C-1''), 150.8 (C-1''', d, $^2J_{P-C} = 6.7$), 153.7 (C-9), 155.4 (C-4, d, $^2J_{P-C} = 6.5$), 156.6 (C-5), 158.8 (C-2), 161.3 (C-7). ^{31}P NMR: $\delta -2.76$.

Compound 5f. Yellow powder, mp 149–150°C, yield 32%. HRMS 650.1384 [M + H]⁺ (calculated for C₃₄H₃₃ClN₃O₅P 649.1300). 1H NMR: δ 2.99 (t, 4 H $^3J_{P-H} = 4.8$, H-11/13), 3.47–3.52 (m, 4 H, H-12/14), 3.89 (s, 3 H, 7-OCH₃), 3.95 (s, 3 H, 5-OCH₃), 6.53 (d, 1 H, $^4J_{H-H} = 2.2$, H-6), 6.74–6.77 (m, 2 H, H-2''/6''), 7.12 (d, 1 H, $^4J_{H-H} = 2.2$, H-8), 7.16–7.19 (m, 2 H, H-3'/5'), 7.28–7.36 (m, 4 H, H-2'''/3'''/5'''/6'''), 7.43–7.50 (m, 3 H, H-3''/5''/4'''), 7.88 (d, 1 H, $^4J_{P-H} = 1.2$, H-3), 8.09 (d, 2 H, $^3J_{H-H} = 1.6$, H-2'/6'). ^{13}C NMR: δ 44.7 (C-12/14), 49.8 (C-11/13, d, $^2J_{P-C} = 5.5$), 55.7 (7-OCH₃), 55.9 (5-OCH₃), 99.5 (C-6), 100.9 (C-8), 107.1 (C-3, d, $^3J_{P-C} = 3.0$), 108.3 (C-10, d, $^3J_{P-C} = 6.5$), 117.9 (C-2''/6''), 120.2 (C-2'''/6''', d, $^3J_{P-C} = 5.0$), 125.2 (C-4''), 125.5 (C-4'''), 127.4 (C-2'/6'), 128.8 (C-3'/5'), 129.0 (C-3''/5''), 129.6 (C-4'), 129.8 (C-3'''/5'''), 138.8 (C-1'), 149.8 (C-1''), 150.7 (C-1''', d, $^2J_{P-C} = 6.7$), 153.6 (C-9), 155.5 (C-4, d, $^2J_{P-C} = 6.7$), 156.6 (C-5), 158.81(C-2), 161.4 (C-7). ^{31}P NMR: $\delta -2.75$.

REFERENCES

1. L. Li, H. K. Wang, S. C. Kuo, T. S. Wu, A. Mauger, C. M. Lin, E. Hamel, and K. H. Kuo, *J. Med. Chem.*, **37**, 3400 (1994).
2. H. Mohamed, A.-M. Mariotte, and A. Boumendjel, *Chem. Pharm. Bull.*, **49**, 1352 (2001).
3. L. J. Huang, M. C. Hsieh, C. M. Teng, K. H. Lee, and S. C. Kuo, *Bioorg. Med. Chem.*, **6**, 1657 (1998).
4. H. Z. Lee, W. C. Lin, F. T. Yeh, and C. H. Wu, *J. Pharmacol.*, **354**, 205 (1998).
5. H. K. Han, R. L. A. De Vruet, J. K. Rhie, K. M. Y. Covitz, P. L. Smith, C. P. Lee, D. M. Oh, W. Sadee, and G. L. Amidon, *Pharmaceut. Res.*, **15**, 1154 (1998).
6. M. Sprecher, R. Breslow, R. Philoosof-Oppeneheimer, and E. Chavet, *Tetrahedron*, **55**, 5465 (1999).
7. X. L. Chen, L. B. Qu, W. F. Li, J. W. Yuan, and Y. F. Zhao, *Phosphorus, Sulfur, and Silicon*, **183**, 603 (2008).
8. C. L. Freel Meyers and R. F. Borch, *J. Med. Chem.*, **43**, 4319 (2000).
9. S. J. Hecker and M. D. Erion, *J. Med. Chem.*, **51**, 2328 (2008).
10. S. Chang, G. W. Griesgraber, P. J. Southern, and C. R. Wagner, *J. Med. Chem.*, **44**, 223 (2001).
11. D. Egron, J. L. Imbach, G. Gosselin, A. M. Aubertin, and C. Perigaud, *J. Med. Chem.*, **46**, 4564 (2003).
12. C. O. Raymundo, L. C. Marcela, and A. T. Ruben, *Monatsh. Chem.*, **130**, 1129 (1999).
13. R. Y. Chen and X. R. Chen, *Heteroatom Chem.*, **4**, 587 (1993).
14. A. Lamouri, F. Heymans, F. Tavet, G. Dive, J. P. Batt, N. Blavet, P. Braquet, and J. J. Godfroid, *J. Med. Chem.*, **36**, 990 (1993).
15. J. P. Yevich, J. S. New, D. W. Smith, W. G. Lobeck, J. D. Catt, J. L. Minielli, M. S. Eison, D. P. Taylor, L. A. Riblet, and D. L. Temple, *J. Med. Chem.*, **29**, 359 (1986).
16. S. W. Choi, D. R. Elmaleh, R. N. Hanson, and A. J. Fischman, *J. Med. Chem.*, **42**, 3647 (1999).
17. C. S. Ananda Kumar, H. Chandru, A. C. Sharada, N. R. Thimmegowda, S. B. Benaka Prasad, M. K. Kumar, and K. S. Rangappa, *Med. Chem.*, **4**, 466 (2008).
18. C. McGuigan, J. C. Thierry, F. Daverio, W. G. Jiang, G. Davies, and M. Mason, *Bioorg. Med. Chem.*, **13**, 3219 (2005).